FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia - Scorecard - MDSpire

FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia

Deseyne delivers smooth, continuous focus across near, intermediate, and distance vision, which is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner.

  • By

  • Conexiant News Staff

  • January 4, 2026

  • 2 min

Share

Clinical Scorecard: FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia

At a Glance

CategoryDetail
ConditionPresbyopia
Key MechanismsExtended depth of focus (EDOF) optical design technology
Target PopulationIndividuals with presbyopia
Care SettingOutpatient, optometry practices

Key Highlights

  • First daily disposable soft contact lens for presbyopia using EDOF technology
  • Delivers smooth, continuous focus across near, intermediate, and distance vision
  • Non-surgical alternative to EDOF intraocular lenses (IOLs)
  • Clinically meaningful improvements in near and intermediate vision
  • High fitting success and rapid patient acceptance in Europe

Guideline-Based Recommendations

Diagnosis

  • Assess visual acuity and symptoms of presbyopia in patients.

Management

  • Consider prescribing Deseyne contact lenses for patients with presbyopia.

Monitoring & Follow-up

  • Evaluate patient comfort and visual performance during follow-up visits.

Risks

  • Monitor for potential adverse reactions or discomfort associated with contact lens wear.

Patient & Prescribing Data

Adults experiencing presbyopia

Deseyne contact lenses provide sustained hydration and comfort throughout the day.

Clinical Best Practices

  • Educate patients on proper contact lens hygiene and care.
  • Ensure appropriate fitting and follow-up assessments for optimal vision correction.

Related Resources & Content

Original Source(s)

FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia

  • by Conexiant News Staff

  • January 4, 2026

Related Content

Everest Expands Ophthalmology Portfolio in China

Everest Medicines acquires rights to presbyopia eye drop

  • June 15, 2026

  • 2 min
Navigating the Irregular Road

Recognizing the signs of corneal ectasia can help with prevention of vision loss, and may decrease the emotional impact and functional deficits that can follow.

CSO Meeting 2026 Highlights Convergence of Innovation and Clinical Practice

More than 300 professionals gathered for three days of innovation, education, and collaboration, highlighting the latest advances in ophthalmic technology and clinical practice

  • May 12, 2026

  • 2 min